Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$13.07 - $18.84 $68,800 - $99,173
-5,264 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$16.56 - $25.46 $87,171 - $134,021
5,264 New
5,264 $105,000
Q3 2020

Nov 13, 2020

SELL
$16.59 - $24.79 $177,280 - $264,905
-10,686 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$16.86 - $23.44 $116,367 - $161,782
6,902 Added 182.4%
10,686 $247,000
Q1 2020

May 14, 2020

SELL
$14.47 - $27.96 $46,810 - $90,450
-3,235 Reduced 46.09%
3,784 $68,000
Q4 2019

Feb 12, 2020

SELL
$15.87 - $23.12 $71,113 - $103,600
-4,481 Reduced 38.97%
7,019 $151,000
Q3 2019

Nov 12, 2019

SELL
$16.91 - $36.27 $3.16 Million - $6.78 Million
-186,991 Reduced 94.21%
11,500 $209,000
Q2 2019

Aug 09, 2019

SELL
$31.0 - $36.3 $389,763 - $456,399
-12,573 Reduced 5.96%
198,491 $7.06 Million
Q1 2019

May 15, 2019

BUY
$31.58 - $46.35 $4.42 Million - $6.48 Million
139,909 Added 196.63%
211,064 $7.09 Million
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $1.57 Million - $2.92 Million
-51,574 Reduced 42.02%
71,155 $2.34 Million
Q3 2018

Nov 13, 2018

BUY
$46.46 - $68.49 $776,997 - $1.15 Million
16,724 Added 15.78%
122,729 $7.48 Million
Q2 2018

Aug 14, 2018

SELL
$46.25 - $104.45 $11.8 Million - $26.7 Million
-255,325 Reduced 70.66%
106,005 $5.18 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $15.8 Million - $29.8 Million
-274,915 Reduced 43.21%
361,330 $38.4 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $4.55 Million - $11.9 Million
-197,502 Reduced 23.69%
636,245 $38 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $14.8 Million - $20 Million
833,747
833,747 $20 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Panagora Asset Management Inc Portfolio

Follow Panagora Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Panagora Asset Management Inc with notifications on news.